comprehensive -WSS

comprehensive

author：focus 2025-09-30 18:42:48 - browse：121

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Obesity drug from Roche shows promise in early study

hotspot

WSS

Hottest summer in 2,000 years puts focus on extreme heat, health

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Lilly’s weekly insulin works as well as daily products, new studies show

Hottest summer in 2,000 years puts focus on extreme heat, health

Adam's Biotech Scorecard: Do Sarepta's exon

ALS treatment from Biogen, Ionis fails in study

focus

comprehensive

knowledge

In Memoriam: Notable people who died in 2023

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

As demand for Covid shots wanes, Moderna seeks its next success

Fertility clinic egg and embryo storage is a disaster

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Insmed lung disease drug hits target in key Phase 3 trial

In age of alternative facts, a scholarly course on calling out crap

Startling documents reveal new facets of Sacklers' opioid empire

Affirmative action in medical school literally saved lives

David Sabatini, ex

focus

Report: NIH

Supreme Court to hear if Covid misinformation is protected speech

HHS suspends federal funding for EcoHealth Alliance

The United States must get value

What will save rural psychiatry services? Higher Medicaid payments

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

entertainment

hotspot

focus

leisure time